Investor Presentaiton

We are increasing registrational portfolio from 6 to 12 potentially first-in-class/best-in-class assets over the next 18 months In registrational studies Registrational studies pending mezigdomide repotrectinib* CD19 NEX T BET Inhibitor (BMS-986158) iberdomide cendakimab GPRC5D CAR T alnuctamab milvexian LPA₁ Antagonist Ill Bristol Myers Squibb *Filed, U.S. PDUFA 11/27/2023 golcadomide AR LDD Not for Product Promotional Use 139

View entire presentation